Emotional Distress and Pathologic Response in Locally Advanced Gastric/GEJ Adenocarcinoma
- Sponsor
- West China Second University Hospital
- Study ID
- NCT07662070
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Emotional Distress
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Pathologic Response
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Not applicable- observational study — OTHERNot applicable- observational study
Study Details
This is a single-center, prospective observational cohort study designed to evaluate the association between pretreatment emotional distress and pathologic response to perioperative immunotherapy in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma. A total of 120 patients planned for neoadjuvant immunotherapy followed by curative surgery will be enrolled. Emotional distress will be assessed using the PHQ-9 and GAD-7 before treatment initiation and at prespecified time points during treatment. Participants will be classified into an emotional distress group or a non-emotional distress group according to predefined criteria. The primary endpoint is major pathological response (MPR). Secondary endpoints include pathological complete response (pCR), R0 resection rate, event-free survival (EFS), recurrence-free survival (RFS), and overall survival (OS). Exploratory analyses will assess dynamic changes in emotional distress and their associations with peripheral stress markers, peripheral immune markers, and tumor immune microenvironment features.
Key Dates
- First listed
- Jun 23, 2026
- Start date
- Jun 26, 2026
- Status verified
- Jun 2026
- Primary completion
- Jul 1, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 120 participants (estimated)
Arms
- Arm: Pretreatment Emotional DistressParticipants with pretreatment emotional distress, defined as a PHQ-9 score of 5 or higher and/or a GAD-7 score of 5 or higher before initiation of perioperative immunotherapy. These participants will receive standard perioperative immunotherapy and routine clinical care according to the treating physician's plan. This observational study will compare pathologic response and clinical outcomes between participants with and without pretreatment emotional distress.
- Arm: No Pretreatment Emotional DistressParticipants without pretreatment emotional distress, defined as a PHQ-9 score lower than 5 and a GAD-7 score lower than 5 before initiation of perioperative immunotherapy. These participants will receive standard perioperative immunotherapy and routine clinical care according to the treating physician's plan. This observational study will compare pathologic response and clinical outcomes between participants with and without pretreatment emotional distress.
Primary Outcome Measure
major pathological response [ Time Frame: Assessed on surgical pathology after completion of neoadjuvant treatment and curative resection, approximately 6 to 12 weeks after treatment initiation ]
Central Contacts
- Qing Li, PhD/MD+8618702848178
Related Studies
- Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric CancerPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsPHASE2 · Recruiting · Apollomics Inc. · Los Angeles, California
- Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal CancerPHASE2 · Recruiting · Dallas VA Medical Center · Dallas, Texas
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor MalignanciesPHASE2 · Recruiting · Dan Zandberg · Pittsburgh, Pennsylvania